The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.
LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.
LifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland
Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.
£1m for translational research projects focussed on children’s rare diseases
Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation
Melanie Lee, LifeArc CEO acknowledges the success of the life sciences and translational research sectors in the UK
Patients with ultra-rare bone marrow disease set to benefit from £1.15m grant from LifeArc and The Aplastic Anaemia Trust
A research grant to investigate the potential of a novel type of “personalised cellular therapy” to reverse the ultra-rare condition, aplastic anaemia
LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases
Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories
Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
The agreement will enable LifeArc to enhance our antibody drug discovery capabilities